Page last updated: 2024-11-05

4-methylimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Methylimidazole (4-MI) is a heterocyclic organic compound. It is a colorless solid, that is soluble in water and has a characteristic odor. It is widely used in the industrial production of pharmaceuticals, polymers, and pesticides. It is also used as a catalyst, a solvent, and a reagent in organic chemistry. 4-MI is a known carcinogen, and it has been linked to various health issues, including cancer, kidney disease, and reproductive problems. It has been shown to be mutagenic in bacterial and mammalian cells. 4-MI is a common contaminant in food, particularly in fried and roasted products, due to the Maillard reaction, which occurs during the heating of food. It is also present in some industrial processes and products, such as the production of coffee, beer, and tobacco. 4-MI is the subject of much research due to its potential health risks. Studies are ongoing to investigate its mechanisms of toxicity and its potential effects on human health.'

4-methylimidazole: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-methylimidazole : Imidazole substituted at position 4 by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13195
CHEMBL ID1230309
CHEBI ID40035
MeSH IDM0080692

Synonyms (74)

Synonym
AC-4534
1h-imidazole, 5-methyl-
hsdb 7757
unii-q64gf9fv4i
ccris 8912
ec 212-497-3
q64gf9fv4i ,
chebi:40035 ,
CHEMBL1230309 ,
4-me-i
4(or 5)-methylimidazole
4(5)-methylimidazole
imidazole, 4-methyl-
nsc40744
nsc-40744
4-methylimidazole
5-methylimidazole
wln: t5m cnj d1
1h-imidazole, 4-methyl-
AL-398/25017073
5-methyl-1h-imidazole
ethanethioic acid, s-3-furanyl ester
s-3-furyl ethanethioate
822-36-6
4MZ ,
NCGC00091437-01
ai3-08274
nsc 40744
einecs 212-497-3
DB03385
4-mei
4(5)-methylimidazole, 98%
4-methyl-1h-imidazole
MLS001065586
smr000568466
nsc 40744-d3
M0636
A840282
EN300-78401
NCGC00091437-02
C19262
HMS3039G17
dtxcid805617
dtxsid9025617 ,
NCGC00258601-01
tox21_201048
cas-822-36-6
AKOS005206795
AKOS006242099
FT-0619088
4mi ,
4-methylimidazole [hsdb]
4-methylimidazole [iarc]
CCG-214463
4-methyl-1-h-imidazole
4-methyl-imidazole
4-methyl imidazole
4-methylimidazol
W-104183
5-methyl-1h-imidazole #
4-methyl-d3-imidazole
Z1945707502
mfcd00005201
4(5)-methylimidazole, analytical standard
CS-D1459
928113-28-4
Q230021
AS-12430
AMY23279
STL185694
5-methyl imidazole
4-methyl-1(3)h-imidazole
bdbm50538684
PD002162

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Here we proposed a method for the determination of 4(5)-MI in soy sauce by combining a modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) extraction with liquid chromatography-mass spectrometry analysis."( Analysis of 4(5)-methylimidazole in soy sauce by a quick, easy, cheap, effective, rugged, and safe approach and liquid chromatography-mass spectrometry.
Li, H; Wang, L; Wu, C; Yu, S, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of oral 4MI was ."( Pharmacokinetics of 4-methylimidazole in sheep.
Karangwa, E; Mitchell, GE; Tucker, RE, 1990
)
0.6
" After gavage at doses of 5, 50 and 150 mg/kg, 4-MZ was readily absorbed with a estimated bioavailability of 60-70%."( Toxicokinetics of 4-methylimidazole in the male F344 rat.
Burka, LT; Yuan, JH, 1995
)
0.63

Dosage Studied

ExcerptRelevanceReference
" Dosing of TCI and TBI to rats resulted within 24-48 hr in neuronal necrosis within the CNS involving the vestibular nucleus, red nucleus, and outer parietal neocortex and ataxia of the hindlimbs."( The relationship between uncoupling of oxidative phosphorylation and neuronal necrosis within the CNS in rats dosed with trihalogenated imidazoles.
Bird, I; Brown, AW; Ray, DE; Verschoyle, RD, 1987
)
0.27
" Two of 3 calves dosed at 200 mg/kg died within 8 and 3/4 hr of dosing."( Effects of 4-methylimidazole in young calves.
Essig, HW; Fairbrother, TE; Kerr, LA, 1987
)
0.66
" Groups of five male and five female Fischer rats and B6C3F1 mice were administered 2MI by dosed feed at 0, 1,200, 3,300, or 10,000 ppm or 4MI at 0, 300, 800, or 2,500 ppm for 15 days, and groups of 10 male and 10 female Fischer rats and B6C3F1 mice were administered 2MI or 4MI at 0, 625, 1,250, 2,500, 5,000 or 10,000 ppm for 14 weeks."( Induction of thyroid lesions in 14-week toxicity studies of 2 and 4-methylimidazole in Fischer 344/N rats and B6C3F1 mice.
Chan, P; Mahler, J; Nyska, A; Travlos, G; Wenk, M, 2006
)
0.57
" No consistent or significant increases in the frequencies of micronucleated erythrocytes were seen in the bone marrow of male rats or mice treated with 4-methylimidazole by intraperitoneal injection, or in peripheral blood samples from male and female mice administered the compound in dosed feed for 14 weeks."( Toxicology and carcinogenesis studies of 4-methylimidazole (Cas No. 822-36-6) in F344/N rats and B6C3F1 mice (feed studies).
, 2007
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
reaction intermediateAny chemical substance produced during the conversion of a reactant to a product.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.45010.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency18.66900.000221.22318,912.5098AID1259243; AID588516
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.28180.011212.4002100.0000AID1030
gemininHomo sapiens (human)Potency0.03660.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)IC50 (µMol)110.00005.00005.00005.0000AID1893771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
protein foldingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
response to bacteriumPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
chaperone-mediated protein foldingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
FK506 bindingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein-macromolecule adaptor activityPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
heat shock protein bindingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
nucleoplasmPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
extracellular exosomePeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1649766Binding affinity to 15N-labeled FKBP51 (1 to 140 residues) (unknown origin) expressed in Escherichia coli OD2N by two-dimensional 1H/15N HSQC NMR spectroscopy2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
AID1649764Binding affinity to 15N-labeled FKBP51 (1 to 140 residues) (unknown origin) expressed in Escherichia coli OD2N assessed as induction of chemical shift perturbations at Ile87 residues by two-dimensional 1H/15N HSQC NMR spectroscopy2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPĪ± Checkpoint.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (120)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (7.50)18.7374
1990's11 (9.17)18.2507
2000's23 (19.17)29.6817
2010's64 (53.33)24.3611
2020's13 (10.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.03 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index99.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other121 (98.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]